Evaluation of the long-term efficacy and safety of dydrogesterone in the treatment of endometriosis/dysmenorrhea
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Endometriosis is currently considered a chronic disease for which long-term medical treatment is needed. The aim of this study was to evaluate the long-term efficacy and safety of dydrogesterone in Chinese women with endometriosis and dysmenorrhea in a real-world setting. METHODS: This was a retrospective study of endometriosis or dysmenorrhea patients who required conservative treatment and who were treated with 10 mg oral dydrogesterone twice a day for 21 consecutive days for 12 consecutive cycles at Shaanxi Provincial People's Hospital from May 2020 to October 2021. Changes in endometriotic lesion volume, dysmenorrhea, SF-36 score, menstrual status, and haemoglobin and Ca125 levels from baseline were measured. The volume change was calculated as follows: [(baseline lesion volume-lesion volume at follow-up)/baseline lesion volume]*100%. Changes > 15%, ± 15%, and >-15% were defined as lesions that were reduced, unchanged, and increased, respectively. Dysmenorrhea was assessed by means of visual analogue scale (VAS) scores. Wilcoxon signed-rank tests were performed to estimate the changes in the above aspects before and after treatment. RESULTS: (p < 0.001). There was no significant difference in the initial lesion diameter among the reduced, enlarged, or unchanged groups (p = 0.082). The VAS score tended to decrease throughout the study (p < 0.001). More than 80% (n = 37, 80.43%) of patients experienced relief of dysmenorrhea after 2 cycles of treatment, and more than 75% (n = 35, 76.09%) of patients stopped using analgesics after 3 cycles of treatment. Almost all patients showed significant improvements in their menstrual cycle regularity, quality of life scores, and haemoglobin levels during treatment (p < 0.001). The incidence of adverse drug reactions was 32.69%, and all reactions were mild to moderate. CONCLUSION: Dydrogesterone can effectively control endometriotic lesions in most women and significantly improve dysmenorrhea and quality of life.
Source: BMC Women s Health
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
Award: G3682322926
OpenAlex ID: W4416205172
